Phibro Animal Health (NASDAQ:PAHC) Reaches New 1-Year High - Time to Buy?

Key Points

• Phibro Animal Health's stock recently reached a new 52-week high of $41.39 during trading, up from a previous close of $39.43.
• Analysts have set varied price targets for the company, with Bank of America at $27.00 and JPMorgan Chase at $35.00, while the consensus rating remains at "Reduce" with an average price target of $28.40.
• The company has announced a quarterly dividend payment of $0.12, yielding approximately 1.2% annually, with a dividend payout ratio of 40.68%.

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) hit a new 52-week high during trading on Wednesday . The stock traded as high as $41.39 and last traded at $41.23, with a volume of 399900 shares trading hands. The stock had previously closed at $39.43.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Bank of America increased their price target on Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a report on Friday, August 29th. Morgan Stanley set a $34.00 price target on Phibro Animal Health in a report on Thursday, August 28th. JPMorgan Chase & Co. upgraded Phibro Animal Health from a "neutral" rating to an "overweight" rating and increased their price target for the company from $25.00 to $35.00 in a report on Monday, July 7th. BNP Paribas upgraded Phibro Animal Health to a "hold" rating in a report on Monday, June 16th. Finally, BNP Paribas Exane upgraded Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price target for the company in a report on Monday, June 16th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Reduce" and an average price target of $28.40.

Phibro Animal Health Price Performance

The company has a market cap of $1.67 billion, a price-to-earnings ratio of 34.94, a price-to-earnings-growth ratio of 1.18 and a beta of 0.89. The company has a fifty day moving average price of $31.22 and a two-hundred day moving average price of $25.14. The company has a current ratio of 2.76, a quick ratio of 1.25 and a debt-to-equity ratio of 2.46.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its quarterly earnings data on Wednesday, August 27th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.05. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The company had revenue of $378.70 million for the quarter, compared to analyst estimates of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. As a group, equities research analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 24th. Stockholders of record on Wednesday, September 3rd will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, September 3rd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.2%. Phibro Animal Health's dividend payout ratio is presently 40.68%.

Hedge Funds Weigh In On Phibro Animal Health

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Phibro Animal Health by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 1,521,520 shares of the company's stock worth $32,500,000 after buying an additional 6,784 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Phibro Animal Health by 0.5% in the 1st quarter. Acadian Asset Management LLC now owns 782,939 shares of the company's stock worth $16,713,000 after buying an additional 4,144 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in shares of Phibro Animal Health by 21.4% in the 4th quarter. Nuveen Asset Management LLC now owns 588,001 shares of the company's stock worth $12,348,000 after acquiring an additional 103,618 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Phibro Animal Health by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 554,927 shares of the company's stock worth $14,175,000 after acquiring an additional 7,841 shares in the last quarter. Finally, Nuveen LLC acquired a new position in shares of Phibro Animal Health in the 1st quarter worth approximately $10,312,000. 99.34% of the stock is owned by institutional investors and hedge funds.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.